Demand for diabetes drugs grows in lesser Chinese cities
This article was originally published in Scrip
Executive Summary
Companies wishing to thrive further in China's robust market for type 2 diabetes treatments should make plans in lower tier cities, suggests research from Datamonitor Healthcare.